Cargando…

Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence Taskforce

OBJECTIVES: To investigate how quickly evidence was incorporated into the Australian living guidelines for COVID-19 during the first 12 months of the pandemic. STUDY DESIGN AND SETTING: For each study concerning drug therapies included in the guideline from April 3, 2020 to April 1, 2021, we extract...

Descripción completa

Detalles Bibliográficos
Autores principales: Hewitt, Jessie, McDonald, Steve, Poole, Alex, White, Heath, Turner, Simon, Turner, Tari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939393/
https://www.ncbi.nlm.nih.gov/pubmed/36813003
http://dx.doi.org/10.1016/j.jclinepi.2023.02.019
_version_ 1784890841522765824
author Hewitt, Jessie
McDonald, Steve
Poole, Alex
White, Heath
Turner, Simon
Turner, Tari
author_facet Hewitt, Jessie
McDonald, Steve
Poole, Alex
White, Heath
Turner, Simon
Turner, Tari
author_sort Hewitt, Jessie
collection PubMed
description OBJECTIVES: To investigate how quickly evidence was incorporated into the Australian living guidelines for COVID-19 during the first 12 months of the pandemic. STUDY DESIGN AND SETTING: For each study concerning drug therapies included in the guideline from April 3, 2020 to April 1, 2021, we extracted the publication date of the study, and the guideline version the study was included in. We analyzed two subgroups of studies as follows: those published in high impact factor journals and those with 100 or more participants. RESULTS: In the first year, we published 37 major versions of the guidelines, incorporating 129 studies that investigated 48 drug therapies informing 115 recommendations. The median time from first publication of a study to incorporation in the guideline was 27 days (interquartile range [IQR], 16 to 44), ranging from 9 to 234 days. For the 53 studies in the highest impact factor journals, the median was 20 days (IQR 15 to 30), and for the 71 studies with 100 or more participants the median was 22 days (IQR 15 to 36). CONCLUSION: Developing and sustaining living guidelines where evidence is rapidly incorporated is a resource- and time-intensive undertaking; however, this study demonstrates that it is feasible, even over a long period.
format Online
Article
Text
id pubmed-9939393
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Author(s). Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-99393932023-02-21 Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence Taskforce Hewitt, Jessie McDonald, Steve Poole, Alex White, Heath Turner, Simon Turner, Tari J Clin Epidemiol COVID-19 series OBJECTIVES: To investigate how quickly evidence was incorporated into the Australian living guidelines for COVID-19 during the first 12 months of the pandemic. STUDY DESIGN AND SETTING: For each study concerning drug therapies included in the guideline from April 3, 2020 to April 1, 2021, we extracted the publication date of the study, and the guideline version the study was included in. We analyzed two subgroups of studies as follows: those published in high impact factor journals and those with 100 or more participants. RESULTS: In the first year, we published 37 major versions of the guidelines, incorporating 129 studies that investigated 48 drug therapies informing 115 recommendations. The median time from first publication of a study to incorporation in the guideline was 27 days (interquartile range [IQR], 16 to 44), ranging from 9 to 234 days. For the 53 studies in the highest impact factor journals, the median was 20 days (IQR 15 to 30), and for the 71 studies with 100 or more participants the median was 22 days (IQR 15 to 36). CONCLUSION: Developing and sustaining living guidelines where evidence is rapidly incorporated is a resource- and time-intensive undertaking; however, this study demonstrates that it is feasible, even over a long period. The Author(s). Published by Elsevier Inc. 2023-03 2023-02-20 /pmc/articles/PMC9939393/ /pubmed/36813003 http://dx.doi.org/10.1016/j.jclinepi.2023.02.019 Text en © 2023 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle COVID-19 series
Hewitt, Jessie
McDonald, Steve
Poole, Alex
White, Heath
Turner, Simon
Turner, Tari
Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence Taskforce
title Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence Taskforce
title_full Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence Taskforce
title_fullStr Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence Taskforce
title_full_unstemmed Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence Taskforce
title_short Weekly updating of guideline recommendations was feasible: the Australian National COVID-19 clinical evidence Taskforce
title_sort weekly updating of guideline recommendations was feasible: the australian national covid-19 clinical evidence taskforce
topic COVID-19 series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939393/
https://www.ncbi.nlm.nih.gov/pubmed/36813003
http://dx.doi.org/10.1016/j.jclinepi.2023.02.019
work_keys_str_mv AT hewittjessie weeklyupdatingofguidelinerecommendationswasfeasibletheaustraliannationalcovid19clinicalevidencetaskforce
AT mcdonaldsteve weeklyupdatingofguidelinerecommendationswasfeasibletheaustraliannationalcovid19clinicalevidencetaskforce
AT poolealex weeklyupdatingofguidelinerecommendationswasfeasibletheaustraliannationalcovid19clinicalevidencetaskforce
AT whiteheath weeklyupdatingofguidelinerecommendationswasfeasibletheaustraliannationalcovid19clinicalevidencetaskforce
AT turnersimon weeklyupdatingofguidelinerecommendationswasfeasibletheaustraliannationalcovid19clinicalevidencetaskforce
AT turnertari weeklyupdatingofguidelinerecommendationswasfeasibletheaustraliannationalcovid19clinicalevidencetaskforce